» Articles » PMID: 27044520

Association of Opioid Agonist Therapy with the Initiation of Antiretroviral Therapy - a Systematic Review

Overview
Publisher Elsevier
Date 2016 Apr 6
PMID 27044520
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: People who inject drugs are at high risk of HIV infection but often face barriers in accessing medical care including access to antiretroviral therapy (ART). Evidence is available about the effectiveness of opioid agonist therapy on drug dependency and risk behaviors. However, it remains scattered regarding access to ART among HIV-positive people who inject drugs. We conducted a systematic review to examine the association of opioid agonist therapy with ART initiation among HIV-positive people who inject drugs.

Methods: We searched the literature for evidence from seven databases. We conducted a narrative synthesis and meta-analysis to examine the association of opioid agonist therapy with ART initiation.

Results: Five out of 2,901 identified studies met the inclusion criteria. Three out of five studies reported that, HIV-positive people receiving opioid agonist therapy initiated ART more than those not receiving opioid agonist therapy. In meta-analysis, opioid agonist therapy was associated with ART initiation among HIV positive people who inject drugs (pooled odds ratio: 1.68; 95% confidence interval: 1.03-2.73).

Conclusions: Opioid agonist therapy is positively associated with ART initiation among HIV-positive people who inject drugs. It is important to scale up opioid agonist therapy among people who inject drugs to improve their ART initiation.

Citing Articles

Characterizing opioid agonist therapy uptake and factors associated with treatment retention among people with HIV in British Columbia, Canada.

Yazdani K, Dolguikh K, Ye M, Trigg J, Joe R, Emerson S Prev Med Rep. 2023; 35:102305.

PMID: 37519440 PMC: 10382920. DOI: 10.1016/j.pmedr.2023.102305.


Assessing the Temporality Between Transitions onto Opioid Agonist Therapy and Engagement with Antiretroviral Therapy in a Cohort of HIV-Positive People Who Use Opioids Daily.

Mitra S, Grant C, Nolan S, Mohd Salleh N, Milloy M, Richardson L AIDS Behav. 2022; 26(6):1933-1942.

PMID: 34977956 PMC: 9859621. DOI: 10.1007/s10461-021-03543-y.


Assessing HIV and overdose risks for people who use drugs exposed to compulsory drug abstinence programs (CDAP): A systematic review and meta-analysis.

Vo A, Magana C, Hickman M, Borquez A, Beletsky L, Martin N Int J Drug Policy. 2021; 96:103401.

PMID: 34389218 PMC: 9027650. DOI: 10.1016/j.drugpo.2021.103401.


Treatment trajectories and barriers in opioid agonist therapy for people who inject drugs in rural Puerto Rico.

Abadie R, McLean K, Habecker P, Dombrowski K J Subst Abuse Treat. 2021; 127:108347.

PMID: 34134865 PMC: 8217715. DOI: 10.1016/j.jsat.2021.108347.


Time-space constraints to HIV treatment engagement among women who use heroin in Dar es Salaam, Tanzania: A time geography perspective.

Saleem H, Likindikoki S, Silberg C, Mbwambo J, Latkin C Soc Sci Med. 2020; 268:113379.

PMID: 32979773 PMC: 7755686. DOI: 10.1016/j.socscimed.2020.113379.